Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 6:35 pm Unchanged | 2023-12-31 | 13G | Orchard Therapeutics plc ORTX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 5:17 pm Purchase | 2024-02-12 | 13D | Werewolf Therapeutics, Inc. HOWL | RA CAPITAL MANAGEMENT L.P. | 6,179,035 15.200% | 2,210,452 (+55.70%) | Filing History |
| 2024-02-14 5:04 pm Unchanged | 2023-12-31 | 13G | Tourmaline Bio, Inc. TRML | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 5:03 pm Sale | 2023-12-31 | 13G | Nektar Therapeutics NKTR | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -1,246,667 (Position Closed) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | RA CAPITAL MANAGEMENT L.P. | 4,163,211 9.700% | 1,373,490 (+49.23%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | RA CAPITAL MANAGEMENT L.P. | 5,551,295 18.700% | 1,777,778 (+47.11%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Chimerix, Inc. CMRX | RA CAPITAL MANAGEMENT L.P. | 8,800,000 9.900% | 2,298,376 (+35.35%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | CureVac N.V. CVAC | RA CAPITAL MANAGEMENT L.P. | 2,744,270 1.200% | -9,501,685 (-77.59%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | ImmunoGen, Inc. IMGN | RA CAPITAL MANAGEMENT L.P. | 26,916,027 9.990% | 4,840,869 (+21.93%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Alpine Immune Sciences, Inc. ALPN | RA CAPITAL MANAGEMENT L.P. | 5,903,234 9.990% | 1,505,866 (+34.24%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Ascendis Pharma A/S ASND | RA CAPITAL MANAGEMENT L.P. | 10,107,400 17.500% | 140,228 (+1.41%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | Avidity Biosciences, Inc. RNA | RA CAPITAL MANAGEMENT L.P. | 2,454,533 3.300% | -3,000,000 (-55.00%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN | RA CAPITAL MANAGEMENT L.P. | 7,809,852 9.000% | 769,230 (+10.93%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC | RA CAPITAL MANAGEMENT L.P. | 11,609,704 18.800% | 1,923,076 (+19.85%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Geron Corporation GERN | RA CAPITAL MANAGEMENT L.P. | 55,145,502 9.990% | 6,722,291 (+13.88%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | GH Research PLC GHRS | RA CAPITAL MANAGEMENT L.P. | 5,587,333 10.700% | 26,215 (+0.47%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | Gracell Biotechnologies Inc. GRCL | RA CAPITAL MANAGEMENT L.P. | 48,600,221 9.990% | -79 (-0.00%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX | RA CAPITAL MANAGEMENT L.P. | 4,724,352 9.990% | 870,485 (+22.59%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | MacroGenics, Inc. MGNX | RA CAPITAL MANAGEMENT L.P. | 4,053,077 6.500% | 288,206 (+7.66%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | RxSight, Inc. RXST | RA CAPITAL MANAGEMENT L.P. | 3,404,285 9.500% | 351,489 (+11.51%) | Filing History |